Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - SALIX PHARMACEUTICALS LTDFinancial_Report.xls
EX-31.1 - SECTION 302 CEO CERTIFICATION - SALIX PHARMACEUTICALS LTDdex311.htm
EX-32.2 - SECTION 906 CFO CERTIFICAITON - SALIX PHARMACEUTICALS LTDdex322.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - SALIX PHARMACEUTICALS LTDdex312.htm
EX-10.84 - FINISHED PRODUCT MANUFACTURING AND SUPPLY AGREEMENT DATED MARCH 31, 2011 - SALIX PHARMACEUTICALS LTDdex1084.htm
EX-10.80 - LICENSE AGREEMENT DATED FEBRUARY 3, 2011 - SALIX PHARMACEUTICALS LTDdex1080.htm
EX-10.82 - OFFICE LEASE DATED FEBRUARY 14, 2011 - SALIX PHARMACEUTICALS LTDdex1082.htm
EX-10.81 - 2010 AGREEMENT RELATED TO PROGENICS'S MNTX IN-LICENSE - SALIX PHARMACEUTICALS LTDdex1081.htm
EX-10.83 - AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT - SALIX PHARMACEUTICALS LTDdex1083.htm
EX-10.29.1 - SECOND AMENDMENT TO LEASE DATED FEBRUARY 11, 2011 - SALIX PHARMACEUTICALS LTDdex10291.htm
EX-10.68.1 - FIRST AMENDMENT TO RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT - SALIX PHARMACEUTICALS LTDdex10681.htm
10-Q - FORM 10-Q - SALIX PHARMACEUTICALS LTDd10q.htm
EX-3.1 - CERTIFICATE OF INCORPORATION, AS AMENDED - SALIX PHARMACEUTICALS LTDdex31.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Salix Pharmaceuticals, Ltd. (the “Company”) for the period ended March 31, 2011 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Carolyn J. Logan, President and Chief Executive Officer, hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.

 

    Date:

 

May 10, 2011

    By:  

/s/ Carolyn J. Logan

       

Carolyn J. Logan

President and Chief Executive Officer